By Robb M. Stewart
Lantheus's shares were under pressure Wednesday after the radiopharmaceutical-focused company trimmed its earnings target for the year.
In premarket trading, the shares were 13% lower after ending the previous session at $104.84, up 17% so far in 2025 and 38% higher over the last 12 months.
The company lowered its guidance for the adjusted earnings in 2025 to between $6.60 and $6.70 a share on revenue of $1.55 billion to about $1.59 billion. In late February, it was aiming for earnings of $7 to $7.20 on revenue of between about $1.55 billion and $1.61 billion.
Lantheus recorded net income of $72.9 million, or $1.02 a share, for the first quarter, down sharply from $131.1 million, or $1.87 a share, a year earlier.
On an adjusted basis, per-share earnings came in at $1.53, below the $1.66 mean estimate of analysts polled by FactSet.
The company's worldwide revenue was little changed for the quarter, edging up less than 1% to $372.8 million but falling short of the $379.7 million that analysts expected.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
May 07, 2025 08:54 ET (12:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.